BioXcel Therapeutics
BTAI
BTAI
88 hedge funds and large institutions have $118M invested in BioXcel Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
64% less capital invested
Capital invested by funds: $325M → $118M (-$207M)
Holders
88
Holding in Top 10
–
Calls
$6.79M
Puts
$5.96M
Top Buyers
| 1 | +$2.33M | |
| 2 | +$2.07M | |
| 3 | +$1.73M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.61M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.26M |
Top Sellers
| 1 | -$4.07M | |
| 2 | -$2.48M | |
| 3 | -$2.44M | |
| 4 |
Renaissance Technologies
New York
|
-$1.75M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.15M |